Good afternoon :)
Place Order
Add to Watchlist

Bharat Parenterals Ltd

BPLPHARMA Share Price

1,355.000.02% (+0.25)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health Care
Pharmaceuticals
Smallcap

With a market cap of ₹933 cr, stock is ranked 1,546

High Risk

Stock is 3.29x as volatile as Nifty

BPLPHARMA Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health Care
Pharmaceuticals
Smallcap

With a market cap of ₹933 cr, stock is ranked 1,546

High Risk

Stock is 3.29x as volatile as Nifty

BPLPHARMA Performance & Key Metrics

BPLPHARMA Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-164.672.750.07%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.235.880.58%

BPLPHARMA Analyst Ratings & Forecast

—
Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

BPLPHARMA Company Profile

Bharat Parenterals Limited is a pharmaceutical company that makes pharmaceutical formulations. Its products include general, beta-lactam, cephalosporins, antiretroviral, and veterinary.

BPLPHARMA Similar Stocks (Peers)

Compare with peers Compare with peers 

BPLPHARMA Similar Stocks (Peers)

Compare with peers Compare with peers 
Sun Pharmaceutical Industries Ltd
SUNPHARMA
PE Ratio
35.36
35.36
1Y Return
13.55%
13.55%
Buy Reco %
86.11
86.11
Cipla Ltd
CIPLA
PE Ratio
23.88
23.88
1Y Return
6.05%
6.05%
Buy Reco %
66.67
66.67
Torrent Pharmaceuticals Ltd
TORNTPHARM
PE Ratio
62.61
62.61
1Y Return
2.36%
2.36%
Buy Reco %
76.00
76.00
Dr Reddy's Laboratories Ltd
DRREDDY
PE Ratio
19.29
19.29
1Y Return
1.43%
1.43%
Buy Reco %
40.00
40.00
Mankind Pharma Ltd
MANKIND
PE Ratio
53.28
53.28
1Y Return
4.62%
4.62%
Buy Reco %
81.25
81.25
Compare with Peers

BPLPHARMA Sentiment Analysis

BPLPHARMA Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

BPLPHARMA Stock Summary · May 2025

The company is strategically positioning itself for future growth by focusing on complex injectables and critical care products, bolstered by a successful US FDA inspection of its new facility. This achievement not only enhances its credibility in regulated markets but also supports ambitious revenue targets, including a projected peak of INR 750 crores by 2030-2031. While operational efficiency is evident with a 19.8% revenue increase and stable EBITDA margins, challenges remain, particularly in revenue recognition from out-licensing agreements and managing trade receivables. Nevertheless, the commitment to sustainable value creation and a diversified product portfolio, alongside careful financial management, underscores a proactive approach to navigating the competitive landscape and capitalizing on emerging market opportunities.

BPLPHARMA Stock Growth Drivers
BPLPHARMA Stock Growth Drivers
6
  • Successful FDA Inspections and Compliance

    The company has successfully completed its first US FDA inspection at its new facility, Innoxel

  • Financial Growth and Performance

    Bharat Parenterals Limited reported a 19.8% increase in stand-alone revenues for FY '25, reaching INR

BPLPHARMA Stock Challenges
BPLPHARMA Stock Challenges
3
  • Challenges in Out-Licensing Agreements

    The company has faced difficulties in realizing milestone payments from out-licensing agreements, with only about

  • Uncertainty in CMO Revenue

    The company has expressed concerns regarding the uncertainty of revenue from Contract Manufacturing Organization (CMO)

BPLPHARMA Forecast

BPLPHARMA Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

BPLPHARMA

BPLPHARMA

Income

Balance Sheet

Cash Flow

BPLPHARMA Income Statement

BPLPHARMA Income Statement

Industry refers to the sub-sector this company belongs to.
Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 7.99%, vs industry avg of 9.99%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.1% to 0.08%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue119.11143.69232.24239.66213.31219.79229.72265.90352.00374.01
Raw Materialssubtract80.5088.81142.09151.88132.47134.39147.23173.57185.93351.87
Power & Fuel Costsubtract1.792.622.703.193.103.213.754.6915.24
Employee Costsubtract11.3712.9415.3715.5814.7515.3718.0022.7949.66
Selling & Administrative Expensessubtract6.4012.3621.6421.6514.0413.8723.6729.0343.60
Operating & Other expensessubtract4.887.658.867.8115.0417.115.044.0543.25
Depreciation/Amortizationsubtract5.795.576.135.886.036.665.889.0235.3234.89
Interest & Other Itemssubtract0.910.940.870.860.771.312.604.0212.9513.87
Taxes & Other Itemssubtract0.593.6813.358.656.746.837.104.21-21.33-20.95
EPS12.0115.9237.0542.1735.5536.5828.4925.05-19.86-8.23
DPS0.000.000.000.000.000.000.751.001.000.00
Payout ratio0.000.000.000.000.000.000.030.04—0.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

BPLPHARMA Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual report

PDF
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
 

BPLPHARMA Stock Peers

BPLPHARMA Past Performance & Peer Comparison

BPLPHARMA Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Bharat Parenterals Ltd-73.982.750.07%
Sun Pharmaceutical Industries Ltd35.365.330.99%
Cipla Ltd23.884.021.03%
Torrent Pharmaceuticals Ltd62.6115.760.91%

BPLPHARMA Stock Price Comparison

Compare BPLPHARMA with any stock or ETF
Compare BPLPHARMA with any stock or ETF
BPLPHARMA
Loading...

BPLPHARMA Holdings

BPLPHARMA Shareholdings

BPLPHARMA Promoter Holdings Trend

BPLPHARMA Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

BPLPHARMA Institutional Holdings Trend

BPLPHARMA Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

BPLPHARMA Shareholding Pattern

BPLPHARMA Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding67.19%0.00%0.54%0.11%32.16%

Oct 2024

Dec 2024

Mar 2025

Jun 2025

BPLPHARMA Shareholding History

BPLPHARMA Shareholding History

JunSepOctDec '24MarJun0.00%0.08%0.08%0.11%0.11%0.11%

BPLPHARMA Insider Trades & Bulk Stock Deals

BPLPHARMA Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing BPLPHARMA stock

smallcases containing BPLPHARMA stock

Looks like this stock is not in any smallcase yet.

BPLPHARMA Events

BPLPHARMA Events

BPLPHARMA Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

BPLPHARMA Dividend Trend

No dividend trend available

BPLPHARMA Upcoming Dividends

BPLPHARMA Upcoming Dividends

Cash Dividend

Ex DateEx DateSep 19, 2025

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 19, 2025

BPLPHARMA Past Dividends

BPLPHARMA Past Dividends

Cash Dividend

Ex DateEx DateJun 25, 2024

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Jun 25, 2024

Cash Dividend

Ex DateEx DateSep 25, 2023

Final
Final | Div/Share: ₹0.75

Dividend/Share

₹0.75

Ex DateEx Date

Sep 25, 2023

BPLPHARMA Stock News & Opinions

BPLPHARMA Stock News & Opinions

Corporate
Bharat Parenterals to convene AGM

Bharat Parenterals announced that the Annual General Meeting(AGM) of the company will be held on 26 September 2025.Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Innoxel Lifesciences successfully completes USFDA inspection of its Vadodara unit

Bharat Parenterals announced that its subsidiary, Innoxel Lifesciences, has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its finished dosage manufacturing facility in Vadodara, Gujarat. This follows the successful completion of the U.S. FDA inspection conducted from April 28 to May 2, 2025. The facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - Liquid Injectables and Oral Liquids. With the receipt of the EIR, Innoxel Lifesciences has also received acceptance of the site for commercial operations for the product(s) under inspection. This milestone reinforces Innoxel's commitment to global quality benchmarks and enhances its capability to supply high-quality pharmaceutical products to regulated markets, such as United States and the European Union.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Bharat Parenterals consolidated net profit rises 542.97% in the June 2025 quarter

Net profit of Bharat Parenterals rose 542.97% to Rs 8.23 crore in the quarter ended June 2025 as against Rs 1.28 crore during the previous quarter ended June 2024. Sales rose 25.39% to Rs 116.00 crore in the quarter ended June 2025 as against Rs 92.51 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales116.0092.51 25 OPM %11.884.85 - PBDT11.154.26 162 PBT2.55-4.77 LP NP8.231.28 543 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Bharat Parenterals to conduct board meeting

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 28 July 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Bharat Parenterals reports consolidated net loss of Rs 4.73 crore in the March 2025 quarter

Net Loss of Bharat Parenterals reported to Rs 4.73 crore in the quarter ended March 2025 as against net loss of Rs 0.30 crore during the previous quarter ended March 2024. Sales rose 53.32% to Rs 103.98 crore in the quarter ended March 2025 as against Rs 67.82 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 12.63 crore in the year ended March 2025 as against net profit of Rs 14.51 crore during the previous year ended March 2024. Sales rose 30.30% to Rs 340.38 crore in the year ended March 2025 as against Rs 261.22 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales103.9867.82 53 340.38261.22 30 OPM %2.141.47 -0.7910.37 - PBDT0.222.51 -91 1.3727.74 -95 PBT-8.30-1.36 -510 -33.9518.72 PL NP-4.73-0.30 -1477 -12.6314.51 PL Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Board of Bharat Parenterals recommends Final Dividend

Bharat Parenterals announced that the Board of Directors of the Company at its meeting held on 12 May 2025, has recommended a Final Dividend of Rs.1 per share (i.e.10%), subject to the approval of the shareholders.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Bharat Parenterals to convene board meeting

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 12 May 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Bharat Parenterals reports consolidated net loss of Rs 1.66 crore in the December 2024 quarter

Net loss of Bharat Parenterals reported to Rs 1.66 crore in the quarter ended December 2024 as against net profit of Rs 3.78 crore during the previous quarter ended December 2023. Sales rose 20.80% to Rs 72.26 crore in the quarter ended December 2024 as against Rs 59.82 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales72.2659.82 21 OPM %5.0511.05 - PBDT3.267.29 -55 PBT-5.505.47 PL NP-1.663.78 PL Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Bharat Parenterals to announce Quarterly Result

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 3 February 2025.Powered by Capital Market - Live

7 months agoCapital Market - Live
Earnings
Bharat Parenterals reports consolidated net loss of Rs 7.51 crore in the September 2024 quarter

Net loss of Bharat Parenterals reported to Rs 7.51 crore in the quarter ended September 2024 as against net profit of Rs 3.52 crore during the previous quarter ended September 2023. Sales rose 19.76% to Rs 71.63 crore in the quarter ended September 2024 as against Rs 59.81 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales71.6359.81 20 OPM %-10.697.22 - PBDT-6.366.29 PL PBT-15.374.54 PL NP-7.513.52 PL Powered by Capital Market - Live

10 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Bharat Parenterals Ltd (BPLPHARMA) today?

    The share price of BPLPHARMA as on 17th September 2025 is ₹1355. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Bharat Parenterals Ltd (BPLPHARMA) share?

    The past returns of Bharat Parenterals Ltd (BPLPHARMA) share are
    • Past 1 week: 1.06%
    • Past 1 month: -6.62%
    • Past 3 months: 13.53%
    • Past 6 months: 35.69%
    • Past 1 year: -15.85%
    • Past 3 years: 307.14%
    • Past 5 years: 207.72%

  3. What are the peers or stocks similar to Bharat Parenterals Ltd (BPLPHARMA)?

    The peers or stocks similar to Bharat Parenterals Ltd (BPLPHARMA) include:

  4. What is the dividend yield % of Bharat Parenterals Ltd (BPLPHARMA) share?

    The current dividend yield of Bharat Parenterals Ltd (BPLPHARMA) is 0.07.

  5. What is the market cap of Bharat Parenterals Ltd (BPLPHARMA) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bharat Parenterals Ltd (BPLPHARMA) is ₹933.69 Cr as of 17th September 2025.

  6. What is the 52 week high and low of Bharat Parenterals Ltd (BPLPHARMA) share?

    The 52-week high of Bharat Parenterals Ltd (BPLPHARMA) is ₹1870 and the 52-week low is ₹802.

  7. What is the PE and PB ratio of Bharat Parenterals Ltd (BPLPHARMA) stock?

    The P/E (price-to-earnings) ratio of Bharat Parenterals Ltd (BPLPHARMA) is -73.98. The P/B (price-to-book) ratio is 2.75.

  8. Which sector does Bharat Parenterals Ltd (BPLPHARMA) belong to?

    Bharat Parenterals Ltd (BPLPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Bharat Parenterals Ltd (BPLPHARMA) shares?

    You can directly buy Bharat Parenterals Ltd (BPLPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.